Clinical Trials Sponsored by Guizhou Tongjitang Pharmaceutical Co.,Ltd

Total 4300 results

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Safety and Tolerability Study of Jaktinib

Myelofibrosis

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Alopecia Areata

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Advanced Solid Tumors | Advanced Hematologic Malignancies

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Lupus Nephritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Suzhou Junde Biotechnology Co., Ltd

Not yet recruiting

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

HER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid Tumor

China, Australia, United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Withdrawn

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) (COVID-19)

COVID-19 | Pneumonia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

First Episode Schizophrenia | Social Function | Cognition Function | Blonanserin

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Schizophrenia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Cream For Atopic Dermatitis

Atopic Dermatitis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Alopecia Areata

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (PSO)

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

COVID-19

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Overweight or Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (DTC)

Differentiated Thyroid Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Myeloid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

SCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Advanced Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Gastric Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

A Study of MSB0254 Injection in Advanced Solid Tumors

Advanced Solid Tumor

China

3

Subscribe